Vita Life Sciences Resultados de beneficios anteriores

Pasado controles de criterios 6/6

Vita Life Sciences ha aumentado sus beneficios a una tasa media anual de 23.9%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 47.3% anual. Los ingresos han ido creciendo a una tasa media de 13.6% al año. La rentabilidad financiera de Vita Life Sciences es de 21%, y sus márgenes netos son de 12.2%.

Información clave

23.9%

Tasa de crecimiento de los beneficios

24.1%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	31.2%
Tasa de crecimiento de los ingresos	13.6%
Rentabilidad financiera	21.0%
Margen neto	12.2%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Mar 22

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Mar 14

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 28

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Dec 20

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

Aug 24

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

May 14

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Mar 18

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Feb 17

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Jan 20

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

Dec 22

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Nov 19

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Jul 14

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Vita Life Sciences. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

ASX:VLS Ingresos, gastos y beneficios (AUD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	74	9	31
30 Sep 23	72	8	30
30 Jun 23	69	7	29
31 Mar 23	68	7	29
31 Dec 22	67	7	29
30 Sep 22	65	8	27
30 Jun 22	64	8	26
31 Mar 22	61	8	25
31 Dec 21	57	8	24
30 Sep 21	54	8	23
30 Jun 21	50	7	22
31 Mar 21	48	6	22
31 Dec 20	46	6	21
30 Sep 20	46	6	22
30 Jun 20	45	5	22
31 Mar 20	44	4	23
31 Dec 19	42	3	23
30 Sep 19	42	2	23
30 Jun 19	41	2	23
31 Mar 19	41	2	22
31 Dec 18	41	2	21
30 Sep 18	40	3	21
30 Jun 18	40	4	21
31 Mar 18	38	3	20
31 Dec 17	37	3	20
30 Sep 17	37	3	20
30 Jun 17	37	3	20
31 Mar 17	38	3	20
31 Dec 16	38	3	20
30 Sep 16	38	4	20
30 Jun 16	38	5	20
31 Mar 16	39	5	21
31 Dec 15	39	4	21
30 Sep 15	38	4	20
30 Jun 15	37	4	20
31 Mar 15	37	6	20
31 Dec 14	37	7	19
30 Sep 14	36	7	19
30 Jun 14	36	7	19
31 Mar 14	36	6	19
31 Dec 13	35	5	18
30 Sep 13	34	4	18
30 Jun 13	33	4	17

Ingresos de calidad: VLS tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (12.2%) de VLS son superiores a los del año pasado (10.6%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lVLS han crecido significativamente en un 23.9% al año.

Acelerando crecimiento: El crecimiento de los beneficios de VLS en el último año (28.2%) supera su media de 5 años (23.9% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de VLS en el último año (28.2%) superó al de la industria Pharmaceuticals 16%.

Vita Life Sciences Resultados de beneficios anteriores

Pasado controles de criterios 6/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

First half 2023 earnings released: EPS: AU$0.074 (vs AU$0.069 in 1H 2022)

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Recent updates

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Upcoming dividend of AU$0.06 per share

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

New minor risk - Insider selling

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Upcoming dividend of AU$0.03 per share at 3.7% yield

First half 2023 earnings released: EPS: AU$0.074 (vs AU$0.069 in 1H 2022)

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

Investor sentiment improves as stock rises 15%

Upcoming dividend of AU$0.033 per share at 3.9% yield

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Non-Executive Chairman exercised options to buy AU$433k worth of stock.

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Upcoming dividend of AU$0.028 per share

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Independent Non-Executive Director Jonathan Tooth has left the company

Investor sentiment improved over the past week

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Investor sentiment improved over the past week

Upcoming Dividend of AU$0.028 Per Share

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

New 90-day high: AU$1.00

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Upcoming Dividend of AU$0.015 Per Share

New 90-day high - AU$0.95

First half earnings released

New 90-day high - AU$0.70

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta